SCHEMBL6426460

SCHEMBL6426460

O=Cc1ccc(-c2ccco2)c(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.60
PTPN2 P17706 2/20 0.60
PTPN6 P29350 2/20 0.60
CFTR P13569 1/20 0.46
POLB P06746 8/20 0.43
L3MBTL1 Q9Y468 6/20 0.43
KDM4E B2RXH2 5/20 0.43
TDP1 Q9NUW8 4/20 0.43
ALDH1A1 P00352 4/20 0.43
GAA P10253 3/20 0.43
ESR1 P03372 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
MAPK1 P28482 1/20 0.43
KEAP1 Q14145 1/20 0.42
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
MAPT P10636 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428107 0.83 CFTR (0.50) PTPN1PTPN2PTPN6CFTRPOLB
SCHEMBL6963441 0.79 PTPN1 (0.57) PTPN1PTPN2PTPN6CFTRPOLB
SCHEMBL18519819 0.76 ALDH1A1 (0.48) PTPN1PTPN2PTPN6POLBKDM4E
SCHEMBL6963436 0.76 PTPN1 (0.49) PTPN1PTPN2PTPN6CFTRPOLB
SCHEMBL29955759 0.76 FOLH1 (0.54) PTPN1PTPN2PTPN6ALDH1A1HSD17B10
SCHEMBL15331022 0.76 FOLH1 (0.54) PTPN1PTPN2PTPN6ALDH1A1HSD17B10
SCHEMBL1673212 0.75 PTPN1 (0.54) PTPN1PTPN2PTPN6CFTRPOLB
SCHEMBL8846999 0.74 ALDH1A1 (0.44) PTPN1PTPN2PTPN6POLBKDM4E
SCHEMBL4141035 0.73 PTPN1 (0.51) PTPN1PTPN2PTPN6CFTRPOLB
SCHEMBL6644180 0.73 ERN1 (0.50) PTPN1PTPN2PTPN6CFTRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines TRIAD THERAPEUTICS, INC. 2005-02-24 US disclosed
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines YU LIN (US) 2004-01-15 US disclosed
WO-2003072033-A2 COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES TRIAD THERAPEUTICS, INC. (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 PTPN1 1174/4885PTPN2 977/4885PTPN6 1019/4885
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 PTPN1 1174/4885PTPN2 977/4885PTPN6 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.